A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Children are evacuated from school 'during an exam' after threat made via email
Fruit Planting Helps Improve Environment and Villagers' Income in SW China's Chongqing
National Great Craftsman Forum Opens in Changsha, C China
Across China: National Fitness Day Events Held Nationwide to Promote Healthy Living
Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
2nd China International Consumer Products Expo Opens in Hainan
Xinhua Headlines: 9 Years on, Economic Ties Closer Among Belt and Road Countries
Mainland a Favorable Destination for Students from HK, Macao, Taiwan
Jon Wysocki dead at 53: Staind drummer passes away
Tsinghua Tops Global Ranking in Three Subjects
Election 2024: Biden and Trump bypassed the Commission on Presidential Debates
China Launches Campaign to Improve People's Digital Skills